myelodysplastic syndromes (MDS) | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

Nikolai Podoltsev, MD, PhD

Podoltsev, Nikolai
Associate Director of the Hematology/Oncology Fellowship Program
Smilow Cancer Hospital at Yale

Dr. Podoltsev practice is focused on myeloid neoplasms including acute myelogenous leukemias (AML), myelodisplastic syndromes (MDS), myeloproliferative neoplasms (MPNs) like polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), chronic myelogenous leukemia (CML) among others. He is providing care for patients with

Thomas Prebet, MD, PhD

Prebet, Thomas
Medical Director of Hematology and Cell Therapy
Smilow Cancer Hospital at Yale

After completing his doctorate in medical hematology and oncology in Lyon, France, Dr. Prebet joined Institut Paoli-Calmettes in Marseille, France and completed a fellowship in Johns Hopkins University (Baltimore, MA, USA) as a Fullbright alumni. Dr. Prebet is currently the director of the inpatient hematology unit and the medical director of the hematology division of Yale

2020 National Patient & Family Conference (virtual)

AAMDSIF is hosting the 2020 National Patient & Family Conference ONLINE over three days, July 17 - 19, 2020. The Conference will feature three days of educational workshops, interesting speakers and support groups for patients with

Save the date!
Event Date: 
Fri, 07/17/2020 to Sun, 07/19/2020

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to

Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

This phase IIa trial studies the side effects of itacitinib when given together with standard treatment (tacrolimus and sirolimus), and to see how well it works in preventing graft-versus-host-disease (GVHD) in patients with acute leukemia, myelodysplastic syndrome or myelofibrosis who are undergoing reduced intensity conditioning donor stem cell transplantation. GVHD is a common complication after donor stem cell transplantation, resulting from donor immune cells recognizing recipients' cells and attacking them.